BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21281426)

  • 1. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease.
    Zachou K; Dalekos GN
    Liver Int; 2011 Mar; 31(3):277-9. PubMed ID: 21281426
    [No Abstract]   [Full Text] [Related]  

  • 2. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection.
    Watanabe M; Shibuya A; Tsunoda Y; Danbara M; Ishii R; Ohsaka M; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Horie R; Higashihara M; Koizumi W
    Liver Int; 2011 Mar; 31(3):340-7. PubMed ID: 21134110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma.
    Cho CH; Hwang WL; Cheng SB; Lee TY; Teng CL
    Ann Hematol; 2011 Jan; 90(1):111-2. PubMed ID: 20407894
    [No Abstract]   [Full Text] [Related]  

  • 4. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.
    Niscola P; Del Principe MI; Maurillo L; Venditti A; Buccisano F; Piccioni D; Amadori S; Del Poeta G
    Leukemia; 2005 Oct; 19(10):1840-1. PubMed ID: 16094417
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.
    Méndez-Navarro J; Corey KE; Zheng H; Barlow LL; Jang JY; Lin W; Zhao H; Shao RX; McAfee SL; Chung RT
    Liver Int; 2011 Mar; 31(3):330-9. PubMed ID: 20738779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
    Muñoz Bertrán E; Pérez Ceballos E; Gómez Espín R; Ortega González I
    Gastroenterol Hepatol; 2010 May; 33(5):377-81. PubMed ID: 20363054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Mitroulis I; Hatzara C; Kandili A; Hadziyannis E; Vassilopoulos D
    Ann Rheum Dis; 2013 Feb; 72(2):308-10. PubMed ID: 22930597
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA: Increased HBV reactivation risk with ofatumumab or rituximab.
    Mitka M
    JAMA; 2013 Oct; 310(16):1664. PubMed ID: 24150447
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge.
    Thompson PA; Tam CS; Thursky K; Seymour JF
    Leuk Lymphoma; 2010 Sep; 51(9):1592-5. PubMed ID: 20807092
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.
    Yeo W; Johnson PJ
    Hepatology; 2006 Feb; 43(2):209-20. PubMed ID: 16440366
    [No Abstract]   [Full Text] [Related]  

  • 11. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance.
    Chew E; Thursky K; Seymour JF
    Leuk Lymphoma; 2014 Apr; 55(4):938-9. PubMed ID: 23772645
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment.
    Kim MG; Park SY; Kim EJ; Kim YM; Kim HY; Lee YK; Zang DY; Kim HJ
    Acta Haematol; 2011; 125(3):121-4. PubMed ID: 21150178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?
    Kusumoto S; Tanaka Y; Mizokami M; Ueda R
    J Clin Oncol; 2013 Dec; 31(35):4480. PubMed ID: 24220561
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
    Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
    Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc.
    Umemura T; Kiyosawa K
    Intern Med; 2006; 45(12):747-8. PubMed ID: 16847362
    [No Abstract]   [Full Text] [Related]  

  • 17. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma.
    Yang SH; Kuo SH
    Ann Hematol; 2008 Apr; 87(4):325-7. PubMed ID: 17932671
    [No Abstract]   [Full Text] [Related]  

  • 18. The immunology of hepatitis B.
    Vierling JM
    Clin Liver Dis; 2007 Nov; 11(4):727-59, vii-viii. PubMed ID: 17981227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis.
    Ghrénassia E; Mékinian A; Rouaghe S; Ganne N; Fain O
    Joint Bone Spine; 2012 Jan; 79(1):100-1. PubMed ID: 21944979
    [No Abstract]   [Full Text] [Related]  

  • 20. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.